Pathstone Holdings LLC Has $1.31 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Pathstone Holdings LLC lifted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 72,598 shares of the company’s stock after purchasing an additional 4,452 shares during the quarter. Pathstone Holdings LLC’s holdings in Teva Pharmaceutical Industries were worth $1,308,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of TEVA. Thrivent Financial for Lutherans raised its holdings in Teva Pharmaceutical Industries by 21.8% during the third quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after buying an additional 40,218 shares during the last quarter. Coronation Fund Managers Ltd. acquired a new stake in shares of Teva Pharmaceutical Industries in the 2nd quarter worth about $1,334,000. Point72 Asset Management L.P. lifted its position in Teva Pharmaceutical Industries by 38.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,319,217 shares of the company’s stock valued at $21,437,000 after acquiring an additional 363,217 shares in the last quarter. Lighthouse Investment Partners LLC acquired a new position in Teva Pharmaceutical Industries during the 2nd quarter valued at about $6,825,000. Finally, WCM Investment Management LLC bought a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $1,051,000. 54.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently issued reports on TEVA. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. lifted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Finally, UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Stock Down 0.1 %

TEVA opened at $16.57 on Friday. Teva Pharmaceutical Industries Limited has a twelve month low of $9.35 and a twelve month high of $19.31. The company’s 50-day moving average price is $17.57 and its two-hundred day moving average price is $17.35. The stock has a market cap of $18.77 billion, a price-to-earnings ratio of -19.49, a PEG ratio of 1.30 and a beta of 0.87. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Insider Buying and Selling

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.